CIP2A and colorectal carcinoma: Regarding drug resistance, we found that CIP2A is associated with drug resistance in CRC, including resistance to 5‐fluorouracil (5‐FU), irinotecan, oxaliplatin, and cetuximab (Teng et al., 2012; Wang et al., 2014).